Clinical applications of serum infliximab trough levels and antibodies to infliximab monitoring in ankylosing spondylitis patients treated with infliximab
10.3760/cma.j.issn.1007-7480.2020.02.009
- VernacularTitle:英夫利西单抗谷浓度及抗体水平监测在维持治疗强直性脊柱炎患者中的临床应用
- Author:
Xindi YU
1
;
Hua WEI
Author Information
1. 江苏省苏北人民医院风湿免疫科，扬州 225001
- From:
Chinese Journal of Rheumatology
2020;24(2):116-119
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between serum concentration of infliximab (IFX) and its impact on clinical efficacy to ankylosing spondylitis (AS) and explore the situation of antibodies to IFX(ATI).Methods:A total of 38 AS patients treated with IFX from Jan 2017 to Dec 2018 at Hospital were enrolled. Serum IFX-trough levels (TLs) and ATI were detected before the 8th IFX treatment. Ankylosing spondylitis disease activity score (ASDAS) were measured at the first, 6th, 8th IFX treatment. The results were analyzed in relation to the clinical response to treatment. One-way analysis of variance, Kruskal-Wallis test, χ2-test, Logistic regression were used for statistical analysis. Results:① ATI against IFX were detected in6 patients (16%). ② The increase of ASDAS in the 8th IFX treatment compared with the 6th IFX treatment was grouped. Based on the receiver operating characteristic curve (ROC), it was calculated that when IFX-TLs was maintained above 0.635 μg/ml, the patient's condition could be kept stable. ③ Logistic regression analysis showed that IFX-TLs was related to BMI [ OR(95% CI)=1.536(1.023, 2.308), P=0.039] and drug combination [ OR(95% CI)=0.218(0.06, 0.797), P=0.021]. Conclusion:The ATI and IFX-TLs is related to the loss of response to IFX treatment. We suggest that the simultaneous measurement of ATI and IFX-TLs may further help to optimizethe therapy in critical situations.
